J&J/Protagonist’s JNJ-2113 Advancing To Pivotal Psoriasis Trial But Efficacy Questions Remain

 
• By Ayisha Sharma

The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.    

Graphic of two people pushing a cube and a cylinder
Cross-Trial Comparisons Presented Some Concerning Caveats • Source: Shutterstock

More from Clinical Trials

More from R&D